Looking to expand its pipeline, Merck to buy eye-disease startup EyeBio; Biohaven protein-degrader drug falls short of investor expectations in early-study test

Taking stock of the drug industry, from the lab to the medicine chest

May 29, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Looking to expand its pipeline, Merck to buy eye-disease startup EyeBio The deal could be worth up to $3 billion and is the latest move from Merck to build its post-Keytruda future. By Andrew Joseph STAT+ | Biohaven protein-degrader drug falls short of investor expectations in early-study test The company called the results of a study of the drug, called BHV-1300, "positive" as a proof of concept but the data fell short of investor expectations. By Adam Feuerstein New obesity drugs are seemingly everywhere. Black Americans feel left out As new weight loss drugs come to market, Black patients and medical experts talk about weight bias, body image, and lack of health insurance. By Anissa Durham Mark Wilson/Newsmakers NIH-funded clinical trials often miss racial, gender diversity enrollment goals, report finds About half of clinical trials were missing information required to explain the goals for the racial and gender makeup of clinical trials. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser